Abstract:Abstract The battle against many cancers and infectious diseases has long been hindered due to the complexity of finding potent and effective drug combinations. With each new drug considered, the number of combinations to potentially test increases exponentially, posing substantial challenges in screening throughput. These challenges further intensify when accounting for the number of doses of each drug that need to be tested in a drug combination matrix (known as matrix density). There is a pressing need to screen large amounts of combinations at sufficient density to discover new therapies for diseases like cancer, but this has traditionally been out of reach. However, the recent widespread adoption of acoustic liquid handling robots has shown promise to overcome these obstacles by allowing for intricate drug screening template designs which were previously not possible to make. Despite these advances, the throughput achieved by these technologies has been limited due to lack of broadly accessible protocols and analytical tools for drug combination screening. We present Combocat, an end-to-end platform that allows for substantial increases in throughput of drug combination screens by combining experimental protocols that can be deployed for acoustic liquid handlers, machine learning algorithms for data imputation, and software that allows for in-depth analysis of results. We first generated a reference dataset of over 250,000 unique drug combination measurements in multiple cancer cell lines. The combination data were collected in a dense format (10×10 combination matrices) using a novel drug-drug template and achieved a dramatic increase in throughput compared to conventional methods. We then used this dataset to build a computational model which allowed us to accurately estimate drug combination effects using sparse measurements and imputing non-measured values with machine learning. The sparse measurements are collected in 1536-well microplates and substantially boost the throughput capabilities of drug-drug screens. As proof-of-concept, we used our method to screen a preclinical model of neuroblastoma with 9,045 drug combinations. This represents 10% the scale of the largest drug combination studies ever reported, achieved using a fraction of the resources, and in dense formats. We validated our findings by re-screening top hits using the fully-measured, non-imputed method and demonstrate the accuracy of our platform. The Combocat platform’s documentation and codebase is open-source, and we also make a GUI available for interactive exploration of screening results. By integrating advanced experimental and computational methods, we provide a generalizable pipeline that will expedite synergy screens and the drug combination discovery process for many diseases. Citation Format: William C. Wright, Paul Geeleher. An ultrahigh-throughput synergy screening platform enables discovery of novel drug combinations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4936.

Abstract IA013: Integrating natural product samples back into drug screening programs

When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

National Cancer Institute (NCI) Program for Natural Product Discovery: Exploring NCI-60 Screening Data of Natural Product Samples with Artificial Neural Networks

Abstract C109: Discovery of New Natural Anti-Tumoral Compounds Using a Parallel Target- and Phenotypic-Driven Screening Approach.

Abstract 4936: An ultrahigh-throughput synergy screening platform enables discovery of novel drug combinations

Protocol for 3D screening of lung cancer spheroids using natural products

Abstract LB071: A phenomics platform combining imaging and artificial intelligence for rapid validation and advancement of novel oncology targets

Natural Products for Cancer Prevention and Interception: Preclinical and Clinical Studies and Funding Opportunities

Abstract 2106: Creating a living public oncology drug resource using PRISM cell line viability screening

The NCI library of traditional Chinese medicinal plant extracts - Preliminary assessment of the NCI-60 activity and chemical profiling of selected species

Abstract 4703: Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA

Abstract 4919: AI-enabled hit selection of drug screening on human pancreatic cancer organoids

Abstract 2944: A high-throughput screening system for identifying therapeutic targets in immuno-oncology

Abstract 3093: Combining lab automation with data analysis automation to enable high-throughput screening of patient-derived organoids

Abstract LB082: A high-throughput immune-oncology screen identifies immunostimulatory properties of low dose chemotherapy in triple negative breast cancer

Abstract C020: Discovery & characterization of small molecules to enhance Natural Killer cell cytotoxicity against solid tumors

Abstract 3102: A high-throughput screening method for discovering potent P-glycoprotein modulators from the chemical library in Tohoku University

High-Throughput Mining of Novel Compounds from Known Microbes: A Boost to Natural Product Screening

Navigating the oncology drug discovery and development process with programmes supported by the National Institutes of Health

Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.

Abstract 90: In vitro functional evaluation of immuno-oncology drug candidates in customized bioassays